Kevin Sayer is the president, chairman, and CEO of Dexcom, a company that develops, manufactures, and distributes continuous glucose monitoring systems.
Sayer joined Dexcom as its president and chief operating officer in 2011, and he became CEO in 2015. In his various roles, he has directed research and development, manufacturing, regulatory, clinical, finance, marketing, and sales functions.
He has played a leading role in developing new technologies in the United States and Europe, including the Dexcom G5 Mobile CGM System and the Dexcom G4 PLATINUM System with Share, among others.
Before joining Dexcom, Sayer was the chief financial officer for medical technology company, Biosensors International. He has also served as an independent healthcare and medical technology industry consultant, as the executive vice president and CFO for Specialty Laboratories, and as the CFO of MiniMed from 1994 until 2001, when it was acquired by Medtronic.
Sayer was recognized on Forbes’ “Innovative Leaders” list in 2019.
He earned both his B.S. and M.S. in accounting and information systems at Brigham Young University.
How old is Kevin R. Sayer?
Mr. Sayer is currently 63 years old. There are 8 older executives and no younger executives at DexCom. The oldest executive at DexCom is Mr. Andrew K. Balo, Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel., who is 73 years old.
How do I contact Kevin R. Sayer?
The corporate mailing address for Mr. Sayer and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at 858-200-0200 and via email at [email protected]
Has Kevin R. Sayer been buying or selling shares of DexCom?
Kevin R. Sayer has not been actively trading shares of DexCom within the last three months. Most recently, Kevin R. Sayer sold 5,535 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $379.88, for a transaction totalling $2,102,635.80.
Who are DexCom's active insiders?
DexCom's insider roster includes Nicholas Augustinos (Director), Andrew Balo (Insider), Andrew Balo (Insider), Quentin Blackford (COO), Richard Doubleday (EVP), Paul Flynn (EVP), Jacob Leach (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), and Jereme Sylvain (CAO).
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 66 times. They sold a total of 269,601 shares worth mmore than $103,622,474.97. The most recent insider tranaction occured on August, 03rd when Andrew K Balo Insider bought 2,757 shares worth more than $1,422,253.59. Insiders at DexCom own 0.5 % of the company.
Information on this page was last updated on 8/3/2021.
